Improving Patient Care Through Translational Mass Spectrometry

Jul 1, 2019 | Blogs, Clinical | 0 comments

Featuring: Wake Forest® Baptist Health

Steven Wong, Ph.D., DABCC (TC), FACB, Past President AACC, Professor of Pathology, serves as Director of the Clinical Chemistry and Toxicology Core Laboratory and is Co-director of the Clinical and Translational Mass Spectrometry Center at Wake Forest School of Medicine with over 37 years of experience.

Elizabeth Palavecino, MD, serves as Medical Director of Clinical Microbiology and is Co-director of the Clinical and Translational Mass Spectrometry Center at Wake Forest School of Medicine.

Q: Please share details about your institution.

Wake Forest Baptist Medical Center is a nationally prominent academic medical center in Winston-Salem, NC, with an integrated health care network.  The Health System includes an 800+ bed hospital serving both an adult and pediatric population with many specialty centers including Cancer and Transplant.

Q: What are your key translational research areas and goals?

We created this translational research unit to look at ways to create new tests for clinical purposes. For example, we have a large population of immunosuppressed patients, so we need a way of testing immunosuppressants or antifungal panels in a rapid way, but also in a very accurate and reliable way. That’s why we started developing these tests using mass spectrometry.  Additional focus areas include acute kidney injury, drug toxicity, breast cancer, renal metabolomics, and personalized medicine approaches.

Q: How has implementing mass spectrometry helped allow your institution to provide the best patient care?

Mass spectrometry is no longer confined to the research lab but is becoming part of the routine testing in clinical labs. It was really a clinical necessity for our lab. Mass spectrometry can give me the answer reliably because it is very specific and only requires a very small volume.  By bringing the test in house, the turnaround time improved drastically, from 3-4 days to 8-24 hours.  That really helped improve patient care.

Q: Why is the SCIEX Citrine™ MS/MS system the right tool to further your diagnostic work?

First is the performance of the mass spec. It has higher sensitivity and is more flexible. Because we are getting it from the same source, it allowed us to establish redundancy in our testing with the two existing mass spec. The enhanced sensitivity allowed us to engage in low-level toxicology testing. The most infamous example right now is fentanyl which is a very potent drug in low concentration. The sensitivity of the newer mass spec allowed us to do an adequate detection of a very highly potent drug like fentanyl.

We have also had extremely positive interactions with both the support service teams within SCIEX as well as the quick response to our needs and are very pleased with that.Learn More About SCIEX Systems >

 

PFAS testing: 2024 in review and what to expect for 2025

For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.

Inside the box: Acoustic ejection mass spectrometry for drug discovery

On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.

Unveiling the power of ZT Scan DIA: Insights from Ludwig Sinn’s presentation at World HUPO Congress 2024

In a recent presentation at the World HUPO Congress 2024, Ludwig Sinn from the Ralser lab shared exciting advancements in proteomics research, focusing on the innovative ZT Scan DIA acquisition modes developed in collaboration with SCIEX. Let us explore the key highlights and benefits of this innovative technology.

Posted by

0 Comments

Submit a Comment

Wordpress Social Share Plugin powered by Ultimatelysocial